GLP-1 Lawsuits and Pharmacy Costs in Personal Injury Cases

James Wong — Founder & CEO, LienScripts | March 4, 2026 | 7 min read

GLP-1 receptor agonist litigation is expanding as adverse effects from medications like semaglutide and tirzepatide generate personal injury claims. LienScripts pharmacy lien services support medication management for plaintiffs in GLP-1 injury cases.

GLP-1 receptor agonist lawsuits represent a growing area of pharmaceutical litigation in 2026, with claims alleging that manufacturers failed to adequately warn about serious adverse effects including gastroparesis, pancreatitis, bowel obstruction, and gallbladder disease. Plaintiffs in GLP-1 litigation often require ongoing medication management to treat the injuries caused by these drugs, creating a secondary pharmaceutical need that pharmacy liens can address. LienScripts pharmacy lien services provide medication access for GLP-1 injury plaintiffs who need treatment for their adverse drug reactions while their cases proceed through litigation.

• GLP-1 receptor agonist lawsuits allege inadequate warnings about gastroparesis, pancreatitis, bowel obstruction, and gallbladder disease
• Plaintiffs in GLP-1 cases often require ongoing medications to manage adverse effects from the drugs
• LienScripts pharmacy liens cover medications needed to treat GLP-1-related injuries during litigation
• Documented medication management for adverse effects strengthens the plaintiff's damages narrative
• LienScripts generates a MERIT (Medication Evaluation & Rationale for Injury Treatment) report for every case, providing pharmacist-signed documentation for demand packages

The GLP-1 Litigation Landscape

GLP-1 receptor agonists, primarily semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), have become some of the most prescribed medications in the United States. As utilization has expanded, reports of serious adverse effects have grown, leading to multidistrict litigation (MDL) and individual lawsuits against manufacturers.

The primary injury claims involve:

Gastroparesis. Severe delayed gastric emptying that causes chronic nausea, vomiting, bloating, and inability to eat normally. This condition may persist after discontinuation of the GLP-1 medication.

Pancreatitis. Inflammation of the pancreas that can be acute and life-threatening or chronic and debilitating.

Bowel obstruction. Intestinal blockage that may require surgical intervention and hospitalization.

Gallbladder disease. Including gallstones and cholecystitis that may require cholecystectomy.

According to James Wong, PharmD, founder of LienScripts, "GLP-1 injury plaintiffs have complex pharmaceutical needs. They need medications to manage the very conditions caused by a medication. Antiemetics for gastroparesis, enzyme supplements for pancreatitis, pain management, and post-surgical medications if intervention was required. The pharmacy lien ensures these secondary treatment costs are covered during litigation."

Medication Needs of GLP-1 Injury Plaintiffs

Plaintiffs injured by GLP-1 medications typically require several categories of treatment medications:

Gastroparesis Management

Patients with GLP-1-related gastroparesis may need prokinetic agents to improve gastric motility, antiemetics for nausea and vomiting control, and nutritional supplements when oral intake is compromised. These medications may be needed for months or years as the condition may not resolve after GLP-1 discontinuation.

Pancreatitis Treatment

Acute pancreatitis management involves pain control, anti-inflammatory medications, and potentially pancreatic enzyme supplements. Chronic pancreatitis requires ongoing enzyme replacement therapy and pain management that may include multiple medication classes.

Post-Surgical Medications

Plaintiffs who undergo surgery for bowel obstruction or gallbladder removal require post-operative pain management, antibiotics, and recovery-phase medications. These surgical cases generate significant pharmaceutical costs.

Supportive Care

Additional medications may include acid suppressants for GI protection, anti-anxiety medications for patients distressed by chronic GI symptoms, and sleep aids for patients whose sleep is disrupted by symptoms.

How the Pharmacy Lien Supports GLP-1 Cases

The LienScripts pharmacy lien covers all medications prescribed to treat injuries caused by the GLP-1 medication. This coverage is particularly important in GLP-1 cases because:

Litigation timelines are long. Mass tort and MDL cases often take years to resolve. During that time, plaintiffs need continuous medication management that the pharmacy lien covers without upfront cost.

Insurance may not cover injury-related treatment. Health insurers may dispute coverage for conditions they attribute to medication use, creating gaps that the pharmacy lien fills.

Multiple medication categories are needed. GLP-1 injury plaintiffs often require medications from several categories simultaneously. The lien covers the entire regimen without the fragmentation of insurance coverage.

The MERIT report from LienScripts documents every medication dispensed to treat the GLP-1-related injuries, providing a clear pharmaceutical treatment timeline for the demand package.

Documentation Strategy for GLP-1 Cases

Establish Causation Timeline

The medication timeline should clearly show when the GLP-1 medication was started, when adverse symptoms began, when the GLP-1 medication was discontinued, and when treatment medications were initiated. The MERIT report captures the treatment medication timeline from lien enrollment forward.

Document Ongoing Treatment Need

GLP-1-related gastroparesis and pancreatitis may require indefinite medication management. Documenting the ongoing pharmaceutical treatment need supports future damages claims for continued medication costs beyond the settlement date.

Differentiate Pre-Existing from Injury-Related

For patients who had the medication documentation for settlement purposes, careful differentiation between pre-existing medication needs and GLP-1 injury-related medications is essential. The MERIT report can be structured to highlight the injury-related medications specifically.

The Growing Caseload

As GLP-1 litigation expands, more attorneys will handle cases involving these medications. Establishing a pharmacy lien relationship through LienScripts early in case development ensures that medication management for adverse effects begins immediately, creating the documentation foundation that supports damages claims throughout the litigation process.